Compare TJX & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TJX | TMO |
|---|---|---|
| Founded | 1962 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.3B | 176.8B |
| IPO Year | 1994 | 1996 |
| Metric | TJX | TMO |
|---|---|---|
| Price | $161.88 | $504.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 19 |
| Target Price | $169.00 | ★ $639.00 |
| AVG Volume (30 Days) | ★ 3.5M | 1.8M |
| Earning Date | 05-20-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.22% | 0.35% |
| EPS Growth | ★ 14.32 | 7.32 |
| EPS | 4.87 | ★ 17.74 |
| Revenue | ★ $29,078,407,000.00 | $20,918,000,000.00 |
| Revenue This Year | $6.75 | $6.32 |
| Revenue Next Year | $5.81 | $5.12 |
| P/E Ratio | $32.40 | ★ $27.57 |
| Revenue Growth | 6.04 | ★ 14.47 |
| 52 Week Low | $119.84 | $385.46 |
| 52 Week High | $162.68 | $643.99 |
| Indicator | TJX | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 55.35 |
| Support Level | $152.69 | $493.64 |
| Resistance Level | $162.63 | $520.66 |
| Average True Range (ATR) | 3.01 | 13.66 |
| MACD | 0.39 | 4.61 |
| Stochastic Oscillator | 95.14 | 94.49 |
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2025, the company generated roughly $56 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).